A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer

Abstract

This first study evaluated the efficacy and safety of imatinib in patients with early androgen sensitive prostate cancer following local therapy. As a single agent at this dosing, imatinib had limited biochemical activity.